- Kane Biotech (KNE) recently published the results of a three-month consumer trial of its DermaKB™ shampoo
- Over 4500 participants signed up for the trial and 1,402 participants completed the questionnaire
- Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products
- Kane Biotech (KNE) is up 2.50 per cent and is trading at C$0.20 at 2:15 pm ET
Kane Biotech (KNE) recently published the results of a three-month consumer trial of its DermaKB™ shampoo.
More than 4500 participants signed up for the trial and 1,402 participants completed the questionnaire.
82 per cent of participants reported seeing an improvement in their symptoms using both the detoxifier and the shampoo, with an average 33 per cent reduction in the severity of symptoms after using only a three oz. sample of either product.
Results of the trial are also available on the DermaKB™ website.
“Over 4,000 participants is a huge consumer trial by anyone’s standard,” explained Kane’s Chief Scientific Officer, Gordon Guay, Ph.D.
“Even more remarkable is the result that of those participants who identified the leading dandruff shampoo as their most often used shampoo prior to the trial, 63 per cent said they preferred DermaKB™ products, either individually or combined after the trial,” added Guay.
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
Kane Biotech (KNE) is up 2.50 per cent and is trading at C$0.20 at 2:15 pm ET.
